EUCTR2007-007764-14-DE进行中（未招募）不适用
An Open-label 52-Week Safety Study of Bicifadine SR in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria to be eligible for the study:
- •1. Male or female, of any race, age 18 years or older.
- •2. Diagnosis of Type-I (insulin dependent) or Type-II (non-insulin dependent) diabetes mellitus.
- •3. Evidence of stable glucose levels over the three months prior to study entry, as documented by a written statement from the subject that their daily glucose levels have been stable and within normal limits, or, if outside normal limits that their diary shows stable values that are acceptable to the Principal Investigator at the site. Alternatively, a written statement from a physician or past laboratory values over the three month period prior to enrollment may be used to demonstrate stable glucose values.
- •4. Evidence of chronic bilateral pain due to diabetic neuropathy, which is defined as pain in the legs or feet with decreased sensation in the feet or decreased/absent ankle jerk deep tendon reflexes.
- •5. Presence of pain due to chronic diabetic neuropathy for at least 6 months prior to enrollment in Protocol B07-001.
- •6. Must have completed all visits of Protocol XTL B07-001 or 12 weeks of treatment at the target dose.
- •7. The primary pain location must be in the feet.
- •8. For females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectable, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study.
- •9. Subject must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •10. Subject must give written informed consent to participate. There must be evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent procedures of the study prior to performing any study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •Subjects must meet all of the following criteria to be eligible for the study:
- •1. Male or female, of any race, age 18 years or older.
- •2. Diagnosis of Type-I (insulin dependent) or Type-II (non-insulin dependent) diabetes mellitus.
- •3. Evidence of stable glucose levels over the three months prior to study entry, as documented by a written statement from the subject that their daily glucose levels have been stable and within normal limits, or, if outside normal limits that their diary shows stable values that are acceptable to the Principal Investigator at the site. Alternatively, a written statement from a physician or past laboratory values over the three month period prior to enrollment may be used to demonstrate stable glucose values.
- •4. Evidence of chronic bilateral pain due to diabetic neuropathy, which is defined as pain in the legs or feet with decreased sensation in the feet or decreased/absent ankle jerk deep tendon reflexes.
- •5. Presence of pain due to chronic diabetic neuropathy for at least 6 months prior to enrollment in Protocol B07-001.
- •6. Must have completed all visits of Protocol XTL B07-001 or 12 weeks of treatment at the target dose.
- •7. The primary pain location must be in the feet.
- •8. For females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectable, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study.
- •9. Subject must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •10. Subject must give written informed consent to participate. There must be evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent procedures of the study prior to performing any study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The presence of any of the following conditions will exclude a subject:
- •1. Early discontinuation, for any reason, from Protocol XTL B07-001
- •2. Presence of other pain that could confound assessment or self-evaluation of the pain due to chronic diabetic neuropathy such as peripheral vascular disease (ischemic pain), neurological disorders unrelated to diabetic neuropathy (e.g., phantom limb pain from amputation), skin condition in the area of the neuropathy that could alter sensation (e.g., plantar ulcer), or other painful conditions (e.g., arthritis, fibromyalgia)
- •3. Symptoms of other painful conditions associated with diabetes such as thoracic radiculopathy or lumbar radiculopathy that could confound assessment or self-evaluation of the pain due to chronic diabetic neuropathy
- •4. Presence of amputations other than toe amputations
- •5. History of lack of adequate therapeutic analgesic response to bicifadine, duloxetine or tricyclic antidepressants
- •6. History of any clinically significant psychiatric or other neurological disorder other than diabetic neuropathy, headache, or migraine headache
- •7. Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g., Alzheimer’s disease or schizophrenia or other psychosis), that in the investigator’s opinion may affect efficacy or safety assessments or may compromise subject safety during the trial
- •8. History (within the last 10 years) of any seizure disorder or epilepsy
- •9. Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within the last 10 years
- •10. Current evidence of clinically important diseases of gastrointestinal, hematopoietic, renal, respiratory, or cardiovascular systems; urinary retention; or glaucoma
- •11. Female subjects who are pregnant and/or breastfeeding or have a positive serum pregnancy test at Visit 1
- •12. History of known alcohol or narcotic substance abuse within 2 years prior enrollment in XTL B07-001
- •13. History of any chronic illness other than diabetes that may interfere with or contraindicate participation in the study, as determined by the investigator
- •14. A body mass index (BMI) of greater than 40
- •15. Clinically relevant illness within the 30 days prior to the Baseline Visit that may interfere with the subject’s ability to complete the study
- •16. Any subject considering or scheduled to undergo any major surgical procedure during the study period
- •The presence of any of the following conditions will exclude a subject:
- •1. Early discontinuation, for any reason, from Protocol XTL B07-001
- •2. Presence of other pain that could confound assessment or self-evaluation of the pain due to chronic diabetic neuropathy such as peripheral vascular disease (ischemic pain), neurological disorders unrelated to diabetic neuropathy (e.g., phantom limb pain from amputation), skin condition in the area of the neuropathy that could alter sensation (e.g., plantar ulcer), or other painful conditions (e.g., arthritis, fibromyalgia)
- •3. Symptoms of other painful conditions associated with diabetes such as thoracic radiculopathy or lumbar radiculopathy that could confound assessment or self-evaluation of the pain due to chronic diabetic neuropathy
- •4. Presence of amputations other than toe amputations
- •5. History of lack of adequate therapeutic analgesic response to bicifadine, duloxetine or tricyclic antidepressants
- •6. History of any clinically significant psychiatric or other neurological disorder other than diabetic neuropathy, headache, or migraine headache
- •7. Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g., Alzheimer’s disease or schizophrenia or other psychosis), that in the investigator’s opinion may affect efficacy or safety assessments or may compromise subject safety during the trial
- •8. History (within the last 10 years) of any seizure disorder or epilepsy
- •9. Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within the last 10 years
- •10. Current evidence of clinically important diseases of gastrointestinal, hematopoietic, renal, respiratory, or cardiovascular systems; urinary retention; or glaucoma
- •11. Female subjects who are pregnant and/or breastfeeding or have a positive serum pregnancy test at Visit 1
- •12. History of known alcohol or narcotic substance abuse within 2 years prior enrollment in XTL B07-001
- •13. History of any chronic illness other than diabetes that may interfere with or contraindicate participation in the study, as determined by the investigator
- •14. A body mass index (BMI) of greater than 40
- •15. Clinically relevant illness within the 30 days prior to the Baseline Visit that may interfere with the subject’s ability to complete the study
- •16. Any subject considering or scheduled to undergo any major surgical procedure during the study period
研究者
相似试验
已完成
Unknown
A study to confirm the safety of overdose of bifidobacteria : a placebo-controlled, randomized, double-blind study.JPRN-UMIN000049771KSO Corporation30
尚未招募
不适用
Evaluation of efficacy (reduction of blood pressure) and safety( adverse events) of Benidipine, Amlodipine and Telmisartan anti- hypertensive drugs in Patients of Hypertension - A comparative study.CTRI/2020/03/024384AIIMS Patna
进行中（未招募）
不适用
An open-label safety study of bifeprunox investigating flexible doses of 20, 30, or 40mg/day in patients with schizophrenia who have completed studies 10206 or 10265 - NDmale and female patients with schizophreniaMedDRA version: 6.1Level: PTClassification code 10039626EUCTR2005-000497-50-ITH. Lundbeck A/S207
招募中
3 期
A clinical trial to determine whether prophylatic administration of Probiotic Bifidobacterium breve to preterm infants reduces the incidence of episodes of Late onset sepsisCTRI/2019/04/018393ational Health Mission
撤回
2 期
An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trialsUlcerative colitisNL-OMON48579Boehringer Ingelheim7